| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04005079 Details | 2022-04-07 Interventional | 3 | 0 | Ofloxacin Pilocarpine Prednisolone Cataract Glaucoma Glaucoma, Open-… Ocular Hyperten… Open Angle Glau… | not performing Trabectomes - | |||
| NCT03809234 Details | 2022-04-07 Interventional | 1 | 14 | Ondansetron Neuralgia Neuropathic Pai… | Adverse effects related to study procedure (not study drug) - | |||
| NCT03684785 Details | 2022-04-07 Interventional | 1/2 | 57 | Cemiplimab Pembrolizumab Carcinoma Carcinoma, Merk… Carcinoma, Squa… Melanoma Squamous Cell C… Advanced or Met… Advanced or Met… Advanced or Met… Advanced or Met… Advanced or Met… | The study was canceled for administrative reasons. - | |||
| NCT02850419 Details | 2022-04-07 Interventional | 2 | 0 | Doxorubicin Liposomal doxor… Breast Neoplasm… Breast Cancer | Administrative - | |||
| NCT04660045 Details | 2022-04-05 Interventional | 2 | 0 | Acalabrutinib Leukemia, Lymph… CLL/SLL Chronic Lymphoc… | Company supplying drug/funding ceased support. - | |||
| NCT04607252 Details | 2022-04-05 Interventional | 2/3 | 12 | Megestrol Megestrol Aceta… Metformin Endometrial Hyp… Hyperplasia Atypical Endome… | Our clinical trial NCT03241888 showed LNG-IUS had a better treatment efficacy than Megestrol
Acetate (MA) alone. The median CR time for MA group, LNG-IUS group and MA plus LNG-IUS group
was 7.0±0.3 months, 4.4±1.0 months and 5.7±1.2 months. - | |||
| NCT03685253 Details | 2022-04-05 Interventional | 1/2 | - | Niacinamide Diabetic Neurop… Peripheral Nerv… Diabetic Neurop… | pilot component of study completed - | |||
| NCT03217838 Details | 2022-04-05 Interventional | 1 | 50 | Azacitidine Pyrazole Venetoclax Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | strategic decision - | |||
| NCT04787250 Details | 2022-04-04 Interventional | 1/2 | 0 | Anti-Bacterial … Antibiotics, An… Arthritis, Infe… Communicable Di… Infections Prosthetic Join… | Changes to protocol design - | |||
| NCT03924245 Details | 2022-04-04 Interventional | 1 | 3 | Entinostat Olaparib Adenocarcinoma Adenocarcinoma,… Carcinoma Carcinoma, Endo… Carcinosarcoma Cystadenocarcin… Endometrial Neo… Fallopian Tube … Mixed Tumor, Mu… Recurrence Fallopian Tube … Fallopian Tube … Fallopian Tube … Fallopian Tube … High Grade Fall… High Grade Ovar… Ovarian Carcino… Ovarian Clear C… Ovarian Endomet… Primary Periton… Recurrent Endom… Recurrent Ovari… Recurrent Prima… | Change in participant landscape and other treatment availability - | |||
| NCT03559010 Details | 2022-04-04 Interventional | 3 | 189 | Norgestrel Contraception | Terminated prematurely due to issues with one of the data collection systems, no impact on
subject safety - | |||
| NCT03008616 Details | 2022-04-04 Interventional | 2/3 | 59 | Digoxin Pre-Eclampsia Severe Preeclam… | Following a recommendation from the Data and Safety Monitoring Board (DSMB), the study was
stopped early for futility. There were no safety concerns raised. - | |||
| NCT02824575 Details | 2022-04-04 Interventional | 1 | 28 | Paclitaxel Rebastinib Breast Neoplasm… Carcinoma Breast Adenocar… Breast Cancer Human Epidermal… Recurrent Breas… Stage IV Breast… | Unfortunately, Deciphera management decided to not move forward with the rebastinib program and
are terminating early. - | |||
| NCT02420795 Details | 2022-04-04 Interventional | 1/2 | 16 | TIC10 compound Lymphoma Lymphoma, Mantl… Lymphoma, Non-H… Recurrence Central Nervous… Gastric Mantle … Recurrent Mantl… Recurrent Non-H… Refractory Mant… Refractory Non-… Splenic Mantle … | Per PI Request - | |||
| NCT01155375 Details | 2022-04-04 Interventional | 3 | 14 | Ferrosoferric O… Ferrous fumarat… Anemia Anemia, Iron-De… Deficiency Dise… Iron Deficienci… Kidney Diseases Renal Insuffici… Iron Deficiency… | Several factors contributed to significant challenges in enrollment and led the Sponsor to
discontinue the AMAG-FER-CKD-251 study as designed. While sample data were collected, it was not run through any analysis to obtain the necessary outcome measure data. As such, summary of the data set is not possible. | |||
| NCT00785798 Details | 2022-04-04 Interventional | 1/2 | 17 | Doxorubicin Liposomal doxor… Vorinostat Lymphoma Refractory Lymp… Relapsed Lympho… | sponsor requested - | |||
| NCT04561076 Details | 2022-04-01 Interventional | 1 | 0 | Myeloma Protein… Paraproteins COVID 19 | Sponsor strategy - | |||
| NCT04037241 Details | 2022-04-01 Interventional | 2/3 | 0 | Capecitabine Gemcitabine Leucovorin Paclitaxel Pancreatic Neop… Malignant Tumor… | Sponsor terminated - | |||
| NCT03418805 Details | 2022-04-01 Interventional | 1 | 31 | Ibuprofen Pain Control | Sponsor's consideration of product development strategies - | |||
| NCT04301310 Details | 2022-03-31 Interventional | 1 | 0 | Rifampin Healthy Partici… | Business objectives have changed - |